stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Operating cash flow
Iovance Biotherapeutics, Inc.'s operating cash flow for fiscal 2025 was −$302.4M, compared with −$353.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$190.0M. Over the past ten years it has ranged from −$361.8M (fiscal 2023) to −$18.4M (fiscal 2015); the current reading is higher than 27% of that period. Iovance Biotherapeutics, Inc. ranks 540th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$302.4M | — |
| FY2024 | −$353.0M | — |
| FY2023 | −$361.8M | — |
| FY2022 | −$292.8M | — |
| FY2021 | −$227.9M | — |
| FY2020 | −$205.1M | — |
| FY2019 | −$158.9M | — |
| FY2018 | −$101.2M | — |
| FY2017 | −$78.7M | — |
| FY2016 | −$32.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$4.5M | — |
| Jun 2026 | −$60.8M | — |
| Mar 2026 | −$72.1M | — |
| Dec 2025 | −$52.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| ABCL AbCellera Biologics Inc. compare | −$94.9M |
| PBLS Parabilis Medicines, Inc. compare | −$118.1M |
| TNGX Tango Therapeutics, Inc. compare | −$143.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$158.4M |
| IOVA Iovance Biotherapeutics, Inc. | −$190.0M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement